Selecta Biosciences, Inc.

Overview

Date Founded

2007

Headquarters

65 Grove Street,Watertown, MA 02472

Type of Company

Public

Employees (Worldwide)

39

Industries

Biotechnology

Company Description

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.

Website

http://www.selectabio.com

Contact Data

Trying to get in touch with decision makers at Selecta Biosciences, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!

In The News

GlobeNewswire

March 1, 2021

Selecta Biosciences to Participate in the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire

January 4, 2021

Selecta Biosciences to Participate in the H.C. Wainwright BioConnect 2021 Conference

PR Newswire

November 23, 2020

3SBio Inc. received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212

Nasdaq

November 20, 2020

Selecta's (SELB) Gene Therapy Gets Orphan Drug Tag From FDA

GlobeNewswire

November 19, 2020

AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic Acidemia

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.

Executives & Employees

Carsten Brunn

President & Chief Executive Officer

Brad Dahms

Chief Financial & Accounting Officer

Lloyd Johnston

Chief Operations Officer

Takashi Kei Kishimoto

Chief Scientific Officer

Peter G. Traber

Chief Medical Officer

Dmitry Ovchinnikov

Managing Director, Selectarus, LLC

Robert S. Langer, Jr.

Co-Founder

Ann K. Donohue

Controller

Chip Michaud

Financial Controller

Marianne Osullivan

Offc Manager

Board of Directors

Carrie S. Cox

Executive Chairman at Humacyte, Inc.

Patrick Zenner

Former Executive Chairman of the Board & Interim Chief Executive Officer at EXACT Sciences Corp.

Timothy A. Springer

Founder at Morphic Therapeutic, Inc.

Tim Barabe

Former Executive Vice President & Chief Financial Officer at Affymetrix, Inc.

Scott Myers

Former President & Chief Executive Officer at AMAG Pharmaceuticals, Inc.

Carsten Brunn

President & Chief Executive Officer at Selecta Biosciences, Inc.

Göran Albert Torstensson Ando

MD at Essex Woodlands Management, Inc.

Aymeric Sallin

Founder & Managing Partner at NanoDimension Management Ltd.

Trending Organizations

Paths to Selecta Biosciences, Inc.

Potential Connections via
Relationship Science

You

Selecta Biosciences, Inc.

Owners & Shareholders

Details Hidden

Polaris Partners

Polaris Partners invests primarily in companies in the consumer technology, digital media/entertainment, e-Commerce, network hardware, software and semiconductors sectors. They invest in seed, early-stage and high growth, middle-market companies.The firm's early-stage investments focus on information technology and life sciences companies. Within the information technology sector, Polaris looks for companies that are developing Internet and broadband infrastructure, enterprise software products, e-Commerce products/services, digital media/entertainment, consumer software, network hardware and network software.In the life sciences sector, the firm looks for companies that are developing medical devices, pharmaceuticals, genomics, proteomics, drug delivery, medical services and consumer products and services.Polaris' private equity efforts focus on high-growth, middle-market companies in industries including technology, healthcare, digital media, consumer products and services and business services.Polaris serves as the lead or co-lead investor in the vast majority of their portfolio companies. The firm participates in minority growth equity investments, recapitalizations with liquidity and LBOs.

Details Hidden

Medical Strategy GmbH

MS is an active growth-oriented investor and manages portfolios invested in global equity with a long-term outlook. The firm focuses on mid- and small-cap companies from the healthcare sector, including pharma, emerging pharma, biotech, genomics, medtech, drug delivery and e-health.MS uses computer models to continuously screen a selection of 700-800 listed companies as well as pre-IPOs for which they systematically collect data in a proprietary database. This information is completed by both in-house and third-party fundamental research

Details Hidden

Endurant Capital Management LP

Endurant Capital Management seeks to generate steady, risk-adjusted returns through long/short investments in small- to mid-cap growth companies in the healthcare sector. The firm’s fund and sub-advised accounts invest principally, but not solely, in equity and equity-related securities that are traded publicly in US markets.

Recent Transactions

Details Hidden

Selecta Biosciences, Inc. raised money in a private placement transaction

Details Hidden

Selecta Biosciences, Inc. raised money in a private placement transaction

Details Hidden

Selecta Biosciences, Inc. issued USD Common Stock

Insider Transactions

Details Hidden

Carsten Brunn

Details Hidden

Peter G. Traber

Details Hidden

Lloyd Johnston

Transaction Advisors

Underwriter

Stifel, Nicolaus & Co., Inc.

Advised onSelecta Biosciences, Inc. issued USD Common Stock

Escrow Agent

American Stock Transfer & Trust Co. LLC

Advised onSelecta Biosciences, Inc. issued USD Common Stock

Investment Advisor

Janney Montgomery Scott LLC

Advised onSelecta Biosciences, Inc. raised money in a private placement transaction

Managing Director

Nathan Thompson

Advised onSelecta Biosciences, Inc. issued USD Common Stock

Legal Advisor

Peter N. Handrinos

Advised onSelecta Biosciences, Inc. issued USD Common Stock

Advisors & Consultants

Legal Advisor

Peter N. Handrinos

Partner at Latham & Watkins LLP

Advisor

Werner Cautreels

Former General Manager-Pharmaceuticals at Solvay SA

Consultant

David L. Siewers

Former Chief Financial Officer & Treasurer at Selecta Biosciences, Inc.

Clients

Roche Holding AG

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Asklepios BioPharmaceutical, Inc.

Asklepios BioPharmaceutical, Inc. operates as a gene therapy-based company. It engages in capsid development, scaled manufacturing, and a portfolio of therapeutic programs. The company was founded by Richard Jude Samulski, Xiao Xiao, and Sheila A. Mikhail in 2001 and is headquartered in Durham, NC.

Spark Therapeutics, Inc.

Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA.

Key Stats and Financials As of 2019

Market Capitalization

$514M

Total Enterprise Value

$37.5M

Earnings Per Share

$-1.22

Revenue

$6.68M

Net Profit

$-55.4M

EBITDAMargin

-755.25%

EBITDA

$-50.4M

Total Equity

$8.4M

Total Debt

$19.3M

TEVNet Income

-0.68x

Enterprise Value / Sales

5.62x

Debt TEV

0.51x

Three Year Compounded Annual Growth Rate Of Revenue

-6.17%

Non-Profit Donations & Grants Received

$698K

12/31/2014

Bill & Melinda Gates Foundation

$3.2M

12/2014

Skolkovo Foundation

$900K

12/31/2013

Bill & Melinda Gates Foundation

Investors

Details Hidden

Polaris Partners

Polaris Partners invests primarily in companies in the consumer technology, digital media/entertainment, e-Commerce, network hardware, software and semiconductors sectors. They invest in seed, early-stage and high growth, middle-market companies.The firm's early-stage investments focus on information technology and life sciences companies. Within the information technology sector, Polaris looks for companies that are developing Internet and broadband infrastructure, enterprise software products, e-Commerce products/services, digital media/entertainment, consumer software, network hardware and network software.In the life sciences sector, the firm looks for companies that are developing medical devices, pharmaceuticals, genomics, proteomics, drug delivery, medical services and consumer products and services.Polaris' private equity efforts focus on high-growth, middle-market companies in industries including technology, healthcare, digital media, consumer products and services and business services.Polaris serves as the lead or co-lead investor in the vast majority of their portfolio companies. The firm participates in minority growth equity investments, recapitalizations with liquidity and LBOs.

Details Hidden

Timothy A. Springer

Founder at Morphic Therapeutic, Inc.

Details Hidden

Rusnano Management Co. LLC

Suppliers

3SBio, Inc. Biotechnology | Shenyang, China

3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products. It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation, and infectious diseases. The company was founded by Jing Lou and Dan Lou in 1993 and is headquartered in Shenyang, China.

Massachusetts Institute of Technology Hospitals & Patient Services | Cambridge, MA

Massachusetts Institute of Technology (MIT) is a private research university located in Cambridge, Massachusetts, United States. MIT has five schools and one college, containing a total of 32 academic departments, with a strong emphasis on scientific, engineering, and technological education and research. Founded in 1861 in response to the increasing industrialization of the United States, the institute used a polytechnic university model and stressed laboratory instruction. MIT was elected to the Association of American Universities in 1934.

Competitors

Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Sangamo Therapeutics, Inc. Biotechnology - Brisbane, CA

Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. We are worldwide leaders in the development of a proprietary technology platform that enables specific regulation of gene expression and gene modification. The basis of this platform is a naturally occurring class of transcription factors, zinc finger DNA-binding proteins (ZFPs) which we can engineer to drive desired therapeutic outcomes. Engineered ZFPs can be linked to functional domains that normally activate or repress gene expression to create ZFP transcription factors (ZFP TFs) capable of turning genes on or off. We can also link ZFPs to nuclease domains to create zinc finger nucleases (ZFNs) which enable precise gene-editing in cells. Engineered ZFNs can modify a cell's DNA at a precise location, thereby facilitating correction or disruption of a specific gene or the targeted addition of a new DNA sequence. Sangamo was founded in 1995, went public in 2000, and trades on the Nasdaq Global Market (SGMO). We are located in Richmond, California, in the Bay Area, the birthplace of biotechnology. We are intimately involved in our community through partnerships with academic institutions, relationships with non-profit organizations and ties to advocacy organizations aligned with improving the quality of life for patients with unmet medical needs within our strategic vision.

Awards & Honors

2014

World Economic Forum - Technology Pioneers